New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|November 19, 2018
Rationale for Genetic Testing in Patients With DLBCL
Author(s)Julie M. Vose, MD, MBA
Julie M. Vose, MD, MBA, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma to better understand their disease and treat the disease properly.
Advertisement
Julie M. Vose, MD, MBA, professor of internal medicine and chief of the division of oncology & hematology at the University of Nebraska Medical Center, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma (DLBCL) to better understand their disease and treat the disease properly.
Advertisement
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5